Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
4d Molecular Therapeutics Inc.
Headquarters: Emeryville, CA, United States of America
Website: http://www.4dmolecularthera...
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: David H. Kirn, MD
Number Of Employees: 227
Enterprise Value: $-99,804,363
PE Ratio: -0.88
Exchange/Ticker 1: NASDAQ:FDMT
Exchange/Ticker 2: N/A
Latest Market Cap: $128,257,600
BioCentury | Oct 22, 2024
Product Development
CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy
FDA will accept Phase I/II data on Fabry gene therapy, obviating need for Phase III trial
BioCentury | Oct 4, 2024
Finance
3Q24 Wrap: Lookin’ up at last
Winners, losers in biotech stock tiers in 3Q24
BioCentury | Aug 6, 2024
Management Tracks
A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
BioCentury | Jul 18, 2024
Data Byte
New AMD data showcase the promise and high bar for vectorized biologics
Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling
BioCentury | Apr 2, 2024
Product Development
Vectorized biologics: are patients and payers ready to swap biologics for gene therapies?
Gene therapy vectors that deliver biologic drugs enter late-state clinical trials
BioCentury | Feb 27, 2024
Management Tracks
Pamela Stephenson to head commercial at Disc
Plus: Seres names Marella Thorell as CFO, and updates from Diakonos and NRx
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Feb 6, 2024
Product Development
Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more
Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
BioCentury | Jan 5, 2024
Management Tracks
Friedman succeeding Hoos at Scorpion
Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
BioCentury | Nov 2, 2023
Product Development
Nov. 2 Quick Takes: Early efficacy signal for IDRx’s GIST therapy
Plus: FDA decision on Lilly’s Alzheiemer’s therapy pushed to 1Q24, and 4D Molecular to test lower doses of 4D-710 after Ph I/II readout
Items per page:
1 - 10 of 40